Farcosolvin (Ambroxol + Guaifenesin + Theophylline)
1. Disclaimer
This drug information is provided for educational and informational purposes only and is not a substitute for the current official Egyptian package leaflet, prescribing information, or advice from a qualified physician or pharmacist. Drug formulations, indications, precautions, age restrictions, regulatory status, and availability may change over time; therefore, the current product packaging and official regulatory information should be checked before use.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
This information should not be used to diagnose, treat, prevent, or manage an individual medical condition, and it should not be interpreted as individualized prescribing or dosing advice.
2. Summary
Farcosolvin is an oral fixed-dose combination marketed by Pharco Pharmaceuticals in Egypt. It combines three pharmacologically different ingredients:
- Ambroxol hydrochloride — mucolytic/secretolytic agent.
- Guaifenesin (guaiphenesin) — expectorant.
- Theophylline anhydrous — methylxanthine bronchodilator.
The currently encountered Egyptian market presentations include Farcosolvin syrup 120 mL and Farcosolvin 24 soft gelatin capsules. Market and pharmaceutical literature consistently report the same labeled strengths for these presentations.
The combination is intended to address cough associated with respiratory secretions together with bronchial narrowing/bronchospasm. However, the presence of theophylline makes the product clinically more interaction-prone than a simple mucolytic/expectorant combination because theophylline has a relatively narrow therapeutic range and highly variable clearance.
3. Brand Name
Farcosolvin®
Known Egyptian market presentations include:
- Farcosolvin Syrup 120 mL
- Farcosolvin 24 Soft Gelatin Capsules
Current market listings continue to identify the product as a Pharco product containing ambroxol + guaifenesin + theophylline.
4. Category
Primary pharmacological category: Mucolytic / expectorant combination with bronchodilator activity.
The product is not an antibiotic and does not have an antimicrobial spectrum.
Its three components belong to different functional categories:
- Ambroxol: mucolytic/secretolytic and mucokinetic activity.
- Guaifenesin: expectorant.
- Theophylline: methylxanthine bronchodilator.
Therefore, describing Farcosolvin simply as an "antitussive" would be inaccurate; it does not primarily suppress the cough reflex.
5. Active Ingredient
Syrup — per 5 mL
- Ambroxol hydrochloride — 15 mg
- Guaifenesin (guaiphenesin) — 30 mg
- Theophylline anhydrous — 50 mg
Soft gelatin capsule — per capsule
- Ambroxol hydrochloride — 30 mg
- Guaifenesin — 100 mg
- Theophylline anhydrous — 60 mg
These strengths are supported by pharmaceutical literature analyzing actual Farcosolvin products and by current market listings.
6. Pharmaceutical Form & Strength
Oral liquid: Farcosolvin syrup, 120 mL.
Strength per 5 mL:
Ambroxol HCl 15 mg + Guaifenesin 30 mg + Theophylline anhydrous 50 mg.
Soft gelatin capsules: Farcosolvin 24 capsules.
Strength per capsule:
Ambroxol HCl 30 mg + Guaifenesin 100 mg + Theophylline anhydrous 60 mg.
The original leaflet reproduced online also describes older pack sizes of 60/120 mL syrup and 12/24 capsules; current Egyptian market listings specifically identify the 120 mL syrup and 24-capsule presentations.
7. Manufacturer & Marketing Authorization Holder
Manufacturer: Pharco Pharmaceuticals, Egypt.
Pharmaceutical studies identify Farcosolvin as manufactured by Pharco Pharmaceuticals, Alexandria, Egypt. Current market listings likewise identify Pharco as the producer.
Marketing Authorization Holder (MAH): Pharco Pharmaceuticals is the manufacturer associated with the product; however, a current publicly accessible Egyptian regulatory record clearly separating the manufacturer from a distinct MAH was not located. Therefore, a separate MAH entity should not be asserted without the current official Egyptian registration record.
8. Mechanism of Action
Ambroxol
Ambroxol modifies the physical properties of bronchial secretions, decreases mucus viscosity, and facilitates mucociliary transport and expectoration. It also has secretolytic/secretomotor effects and can stimulate pulmonary surfactant secretion.
Guaifenesin
Guaifenesin is an expectorant that increases the volume and decreases the viscosity of respiratory secretions, thereby facilitating their clearance by coughing. It is rapidly absorbed and metabolized after oral administration.
Theophylline
Theophylline is a methylxanthine with bronchodilator activity. Its pharmacological effects include relaxation of bronchial smooth muscle. It also has effects on respiratory muscle function and inflammatory signaling, but the exact clinical contribution of these mechanisms varies with concentration and disease state.
Combined effect
The combination therefore provides mucolytic/secretolytic + expectorant + bronchodilator actions.
The original wording that the three ingredients "act synergistically" should be treated cautiously. Clinical evidence exists for Farcosolvin in specific respiratory settings, including a randomized study in acute exacerbations of chronic bronchitis, but this does not establish that every claimed pharmacodynamic effect is synergistic in all respiratory diseases.
9. Spectrum of Activity
No antimicrobial spectrum applies.
Farcosolvin does not act as an antibacterial, antiviral, antifungal, or antiparasitic medicine.
Its pharmacological activity concerns:
- Reduction/modification of viscous respiratory secretions.
- Facilitation of mucus clearance and expectoration.
- Bronchodilator activity through theophylline.
Therefore, statements implying that Farcosolvin treats the underlying infectious organism would be inaccurate.
10. Pharmacokinetics
Because Farcosolvin is a fixed-dose combination, pharmacokinetics should be considered separately for each active ingredient.
Ambroxol
Ambroxol is rapidly absorbed orally. It is extensively distributed into tissues, with high protein binding, and concentrations are prominent in the lungs. It undergoes hepatic metabolism, including pathways involving CYP3A4, and glucuronidation. Its terminal plasma half-life is approximately 10 hours in commonly cited pharmacokinetic data. Renal excretion is mainly in the form of metabolites/conjugates rather than unchanged drug.
Guaifenesin
Guaifenesin is readily absorbed from the gastrointestinal tract and is rapidly metabolized and excreted in urine. A commonly reported plasma half-life is approximately 1 hour.
Theophylline
Theophylline is rapidly and almost completely absorbed from immediate-release oral formulations. It is extensively metabolized in the liver, with substantial inter-individual variability in clearance and half-life. Its mean half-life in adults is commonly around several hours, but it varies considerably according to age, smoking, illness, hepatic function, interacting drugs, and other factors.
Theophylline reaches steady state after repeated administration, but the time required varies according to its clearance. Because of its variable pharmacokinetics and relatively narrow therapeutic margin, clinically important changes can occur when interacting medicines are started or stopped.
11. Indications
The historical Farcosolvin leaflet describes use for productive and non-productive cough associated with viscid respiratory secretions and bronchospasm in acute and chronic respiratory diseases, including conditions such as bronchitis, asthmatic bronchitis, bronchopneumonia, pneumonia, emphysema, bronchiectasis, and atelectasis.
However, these historical label indications should not automatically be interpreted as current evidence-based treatment recommendations for every listed disease.
A clinical study specifically evaluated Farcosolvin syrup in acute exacerbations of chronic bronchitis and reported improvement in cough and breathlessness compared with a guaifenesin-containing control regimen.
The product should therefore be understood as a symptomatic respiratory preparation rather than as treatment for the underlying infectious, inflammatory, or structural cause of a respiratory disease.
12. Administration
Farcosolvin is administered orally.
Historical product information reports:
- Adults and children above 12 years: 1–3 teaspoonfuls of syrup or 1–2 capsules, three times daily.
- The older reproduced leaflet also gives pediatric syrup dosing for younger children.
Important update concerning pediatric use
The historical Farcosolvin material available online states dosing beginning at 1 year of age, but this should not be presented as an automatically current or universally safe pediatric recommendation.
Contemporary ambroxol product information in several regulatory systems generally restricts use below 2 years except under medical advice, reflecting safety concerns associated with mucolytic use in very young children.
Therefore, the historical 1–3-year Farcosolvin dose should be regarded as legacy product-label information requiring confirmation against the current Egyptian package leaflet, rather than reproduced as an unconditional modern recommendation.
The dose should not be independently increased, decreased, or extended because the product contains theophylline, whose clearance varies substantially between individuals.
13. Method of Preparation
Syrup
The marketed 120 mL product is a ready-to-use oral syrup; no extemporaneous reconstitution procedure was identified in the reliable sources reviewed.
Use an appropriate measuring device rather than relying on an ordinary household spoon.
Soft gelatin capsules
The capsules are an oral soft-gelatin dosage form and are intended to be administered according to the product instructions.
No special preparation or dilution procedure should be inferred without the current manufacturer leaflet.
14. Contraindications
The principal established contraindication is:
- Known hypersensitivity to ambroxol, guaifenesin, theophylline, or another component of the specific formulation.
Theophylline product information specifically lists hypersensitivity to theophylline or formulation components as a contraindication.
Conditions such as peptic ulcer disease, significant cardiac disease, hepatic impairment, renal impairment, seizure disorders, and other conditions are more appropriately treated as warnings/precautions or situations requiring medical supervision, rather than automatically described as absolute contraindications for the entire combination.
15. Warnings & Precautions
Particular caution is warranted because of the theophylline component.
Important considerations include:
- Peptic ulcer disease: theophylline may aggravate the condition.
- Cardiac arrhythmias: theophylline can increase the risk of clinically important cardiovascular effects.
- Seizure disorders: theophylline can lower the seizure threshold and requires caution.
- Hepatic impairment: reduced theophylline clearance can increase systemic exposure.
- Heart failure: theophylline clearance can be substantially reduced.
- Fever: sustained fever can decrease theophylline clearance and increase exposure.
- Smoking cessation: stopping smoking can substantially reduce theophylline clearance, potentially increasing serum concentrations.
- Smoking: chronic tobacco smoking can increase theophylline clearance.
Ambroxol has also been associated with rare but potentially severe cutaneous adverse reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis. Progressive rash, blistering, or mucosal lesions require immediate discontinuation and medical evaluation.
In patients with impaired bronchial clearance and very copious secretions, mucolytic treatment should be used cautiously because increased mobilization of secretions may potentially contribute to airway obstruction.
16. Drug Interactions
The most clinically important interaction burden comes from theophylline.
Examples of medicines or factors that may increase theophylline exposure include:
- Cimetidine
- Ciprofloxacin
- Clarithromycin / erythromycin and certain other macrolides
- Disulfiram
- Verapamil
- Some other inhibitors of theophylline metabolism.
Medicines/factors that can reduce theophylline exposure include:
- Rifampicin/rifampin
- Carbamazepine
- Phenytoin
- Phenobarbital
- Smoking/tobacco exposure
- Certain enzyme-inducing conditions or medications.
Stopping a medicine that previously increased theophylline clearance can itself cause theophylline concentrations to rise.
Because of this variability, patients receiving theophylline should inform healthcare professionals whenever medicines are started, stopped, or changed. In appropriate clinical situations, serum theophylline concentration monitoring may be required.
Guaifenesin itself has relatively few established clinically important drug interactions.
No major routine interaction specific to ambroxol and the other two components has been established that would justify claiming a universal interaction-free combination.
17. Side Effects
The original Farcosolvin leaflet states that the product is generally well tolerated and reports transient nausea or vomiting as rare adverse effects.
However, the adverse-effect profile should not be limited to that historical statement because the three active ingredients have their own recognized adverse effects.
Possible gastrointestinal effects
- Nausea
- Vomiting
- Abdominal discomfort or gastrointestinal irritation
Guaifenesin commonly causes nausea and vomiting in some patients.
Theophylline-related effects
Excessive exposure can produce:
- Nausea and vomiting
- Headache
- Insomnia
- Tremor/nervousness
- Tachycardia or palpitations
- More serious toxicity, including arrhythmias and seizures in severe poisoning.
Ambroxol-related effects
Possible effects include gastrointestinal symptoms and hypersensitivity reactions. Rare severe skin reactions have been reported and require immediate medical attention.
Thus, the statement "Farcosolvin is safe and well tolerated" is too absolute when used without qualification. A more accurate formulation is that the product has been reported as generally tolerated, while clinically important adverse reactions remain possible, particularly because of theophylline.
18. Use in Special Populations
Pregnancy
The historical Farcosolvin information recommends use during pregnancy only when clearly indicated.
Because the combination contains theophylline and because pregnancy can alter theophylline pharmacokinetics, use during pregnancy should be based on a clinician's assessment of benefit versus risk rather than routine self-medication. Theophylline clearance may decrease during late pregnancy.
Lactation
The historical product information advises use in nursing mothers only when clearly indicated. Theophylline passes into breast milk.
Children
Pediatric use requires particular caution. The historical Farcosolvin leaflet gives doses beginning at 1 year, but contemporary ambroxol labeling in several regulatory systems generally restricts use below 2 years except under medical advice.
Therefore, the current Egyptian package leaflet should be checked before presenting any pediatric dose as current.
Elderly
Theophylline clearance generally decreases with age, which can increase systemic exposure and adverse-effect risk.
Hepatic impairment
Theophylline clearance can be substantially reduced in significant hepatic disease; increased exposure may require clinical monitoring and dose adjustment by a healthcare professional.
Renal impairment
The effect depends on the individual ingredient and severity of renal dysfunction. Severe renal disease is specifically listed in historical Farcosolvin precautions because of the combination's theophylline component. Ambroxol metabolites may also accumulate in severe renal impairment.
19. Storage Conditions
Available Farcosolvin product information specifies storage at approximately 15–30°C and keeping the medicine out of reach of children.
Some current market information additionally advises protection from light and specifically states not to refrigerate the syrup.
Because storage requirements can depend on the specific formulation and packaging, the current package label should take precedence.
20. Additional Sections
Current Egyptian market status
Current Egyptian medicine listings identify:
- Farcosolvin 24 caps
- Farcosolvin syrup 120 mL
with Pharco as the manufacturer and ambroxol + guaifenesin + theophylline as the active combination.
Evidence note
A randomized controlled study involving 100 patients evaluated Farcosolvin syrup in acute exacerbations of chronic bronchitis and reported improvement in cough and breathlessness compared with the control group receiving guaifenesin plus standard treatment. This provides clinical evidence for that particular setting, but it does not establish efficacy for every disease historically listed in the product leaflet.
Regulatory-label note
The widely reproduced Farcosolvin leaflet available online appears to be an older product text. Because a current official Egyptian electronic package leaflet was not located during this review, historical dosage, age limits, pack sizes, and indications should not be represented as definitively identical to the 2026 Egyptian regulatory label without verification against the current physical package insert.
Important pharmacological point
Theophylline is the component that most strongly determines the interaction and toxicity profile of this combination. Its clearance is highly variable and can change substantially with smoking, fever, hepatic disease, heart failure, age, and interacting medicines.
21. Frequently Asked Questions (FAQ)
What is Farcosolvin used for?
It is a combination respiratory preparation containing a mucolytic, an expectorant, and theophylline, intended for symptomatic respiratory conditions involving mucus/secretions and bronchial narrowing according to the applicable product information.
Is Farcosolvin an antibiotic?
No. It has no antibacterial, antiviral, or antifungal activity and should not be considered a substitute for treatment directed at a respiratory infection when such treatment is clinically required.
What are the active ingredients?
Ambroxol hydrochloride, guaifenesin, and theophylline anhydrous.
What is the strength of Farcosolvin syrup?
Each 5 mL contains 15 mg ambroxol hydrochloride + 30 mg guaifenesin + 50 mg theophylline anhydrous.
What is the strength of Farcosolvin capsules?
Each soft gelatin capsule contains 30 mg ambroxol hydrochloride + 100 mg guaifenesin + 60 mg theophylline anhydrous.
Does Farcosolvin stop coughing?
It is not primarily a cough suppressant. By modifying and mobilizing respiratory secretions, it may make coughing more productive and facilitate clearance of mucus.
Is Farcosolvin suitable for children?
The answer depends on age, formulation, clinical condition, and the current product labeling. Older Farcosolvin information included dosing from 1 year, but contemporary ambroxol labeling commonly restricts use below 2 years except under medical advice. Therefore, pediatric use should be confirmed against the current Egyptian leaflet and healthcare-professional advice.
Can Farcosolvin interact with other medicines?
Yes. The most important interactions are related to theophylline. Drugs such as ciprofloxacin, cimetidine, clarithromycin/erythromycin, rifampin, carbamazepine, phenytoin, and others can alter theophylline exposure.
Why is smoking relevant to Farcosolvin?
Smoking can increase the clearance of theophylline. Conversely, stopping smoking can substantially reduce clearance and potentially increase theophylline exposure.
Can Farcosolvin be used during pregnancy?
The historical product information recommends use only when clearly indicated. Because of the combination and particularly theophylline component, pregnancy use should be determined by a healthcare professional.
What should be done if symptoms persist?
Persistent, worsening, recurrent, or unexplained cough—especially when accompanied by significant breathlessness, fever, chest pain, blood in sputum, or wheezing—requires appropriate medical assessment rather than prolonged self-treatment.
22. References
-
Farcosolvin clinical study: Yakoot M, Salem A, Omar A. Clinical efficacy of Farcosolvin syrup (ambroxol–theophylline–guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis. Clinical Epidemiology and Global Health/International COPD-related publication.
-
Farcosolvin pharmaceutical composition: Analytical studies confirming Farcosolvin syrup as ambroxol 15 mg + guaifenesin 30 mg + theophylline 50 mg per 5 mL and capsule strength of ambroxol 30 mg + guaifenesin 100 mg + theophylline 60 mg.
-
DailyMed — Theophylline: Pharmacokinetics, warnings, smoking effects, toxicity, and clinically significant drug interactions.
-
DailyMed — Guaifenesin: Absorption, metabolism, elimination, and adverse-effect information.
-
Saudi Food and Drug Authority drug information: Ambroxol pharmacokinetics, warnings, pediatric restrictions, and serious cutaneous reactions.
-
PubMed — Ambroxol metabolism: Evidence identifying CYP3A4 as the predominant CYP isoform involved in formation of dibromoanthranilic acid from ambroxol.
-
Current Egyptian market listings: Farcosolvin 24 capsules and Farcosolvin syrup 120 mL listings identifying Pharco and the ambroxol + guaifenesin + theophylline combination.
-
Egyptian Drug Authority: Current OTC regulatory list reviewed as part of the verification process. The absence of Farcosolvin from the portion of the publicly accessible list retrieved here should not by itself be interpreted as proof of prescription/OTC status without the complete current regulatory record.
Verification conclusion
The core composition and pharmaceutical forms in the original text are supported: Farcosolvin syrup 120 mL contains 15/30/50 mg per 5 mL, and the soft gelatin capsule contains 30/100/60 mg of ambroxol/guaifenesin/theophylline respectively.
The original text, however, should not be reproduced unchanged as a modern drug monograph. The most important corrections are:
- The statement that the product is simply "safe and well tolerated" is too absolute.
- Theophylline-related interactions and toxicity considerations need substantially more emphasis.
- The historical pediatric dosing beginning at 1 year should not be presented as an unconditional current recommendation.
- The original list of indications should be identified as historical product-label information rather than automatically treated as contemporary evidence-based indications for every listed disease.
- "Synergistic" should not be stated as an established universal property of the three-drug combination.
- Farcosolvin has no antimicrobial spectrum.
- Ambroxol's rare but potentially serious cutaneous reactions should be included.
- The manufacturer is supported as Pharco Pharmaceuticals, Egypt, while a separately identifiable current MAH could not be independently verified from the publicly accessible sources reviewed.
- The current Egyptian market evidence supports the existence of Farcosolvin 24 caps and Farcosolvin syrup 120 mL with the stated composition, but the exact 2026 regulatory leaflet should still be checked against the physical package before any claim is presented as the current official Egyptian label.